ClinicalTrials.gg
CompletedNCT02589405BenzacUpdated Feb 18, 2021Results posted

Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris

A Phase 4 interventional study of Benzoyl Peroxide and Dermotivin® Soft Liquid cleanser in Acne Vulgaris, sponsored by Galderma R&D. Completed at 1 site in Germany. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing Benzoyl Peroxide in Acne Vulgaris — none open to participants now, 1 under way, none of them phase 3. Benzoyl Peroxide · Acne Vulgaris.

Enrollment
24th of 33
50 · median 90
Started
2015
with 4 others
Phase 4
16 of 33
none open now
Registered
27th of 33
by date
Lead sponsor
7 of 33
Galderma R&D

Among the 33 studies testing Benzoyl Peroxide in Acne Vulgaris, this one is the 24th largest by enrollment, is one of 5 that started in 2015, is one of 16 in phase 4, and was the 27th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 33 studies testing Benzoyl Peroxide in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About Benzoyl Peroxide

Benzoyl Peroxide: first FDA approval 1984 (BENZAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing Benzoyl Peroxide in Acne Vulgaris as a file.
02

Study summary

The aim of this study is to evaluate a complete acne regimen consisting of a medication (Benzaknen® 5% Gel), and 2 cosmetic products Dermotivin® Soft Liquid soap and Cetaphil® Dermacontrol Moisturizer SPF30 in patients with acne.

Read the detailed description

The main objective of this study is to evaluate subject satisfaction with the treatment regimen comprising Benzaknen® 5% Gel in association with 2 cosmetic products including a foam soap, Dermotivin® Soft Liquid soap, and a non comedogenic moisturizer, Cetaphil® Dermacontrol Moisturizer SPF30, in patients with mild to moderate acne, after 12 weeks of treatment.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject of any ethnic background of 12 years or older.
  • Subject with mild or moderate facial acne vulgaris defined as an Investigator Global Assessment (IGA) score at 2 or 3 on a 0-4 scale.
  • Subject with any skin phototype according to T.B. Fitzpatrick skin phototype definitions.

Exclusion criteria

Exclusion Criteria:

  • Subject with severe acne (IGA>3) with nodules, cysts, scars or extra-facial lesions,
  • Female subject who is pregnant, lactating or planning a pregnancy during the study,
  • Subject susceptible to take a treatment during the study except inhaled or topic when needed to treat a condition outside the face,
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Benzaknen treatment regimen

    Benzac® 5% Gel (once daily) + Dermotivin® Soft Liquid soap (twice daily) + Cetaphil® Dermacontrol Moisturizer SPF30 (once daily)

    Drug: Benzoyl Peroxide · Other: Dermotivin® Soft Liquid cleanser · Other: Cetaphil® Dermacontrol Moisturizer SPF30

Interventions

  • OtherDermotivin® Soft Liquid cleanser
  • OtherCetaphil® Dermacontrol Moisturizer SPF30
06

What researchers measure

Primary outcomes

  1. Number of Participants Satisfied and Very Satisfied With Regimen

    Number of subjects satisfied and very satisfied with the three-part treatment regimen

    Time frame: 12 weeks

07

Results

Posted Feb 11, 2019

Participant flow

Participant flow — Overall Study
MilestoneThree-part Treatment Regimen
Started50
Completed46
Not completed4
Withdrew: Adverse event3
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants Satisfied and Very Satisfied With Regimen

Number of subjects satisfied and very satisfied with the three-part treatment regimen

Time frame:
12 weeks
Reported as:
Number · participants
Number of Participants Satisfied and Very Satisfied With Regimen
participantsTreatment Regimen
Number of Participants Satisfied and Very Satisfied With Regimen42

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Three-part Treatment Regimen0/50 (0%)1/50 (2%)13/50 (26%)
Most frequent serious events
Most frequent serious events
EventThree-part Treatment Regimen
HypersensitivityImmune system disorders1/50
Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders1/50
Most frequent other events
Showing 10 of 14
Most frequent other events
EventThree-part Treatment Regimen
NasopharyngitisInfections and infestations4/50
Skin irritationSkin and subcutaneous tissue disorders3/50
LacerationInjury, poisoning and procedural complications1/50
Radius fractureInjury, poisoning and procedural complications1/50
BlepharitisImmune system disorders1/50
DiarrhoeaGastrointestinal disorders1/50
AcneSkin and subcutaneous tissue disorders1/50
RashSkin and subcutaneous tissue disorders1/50
Skin exfoliationSkin and subcutaneous tissue disorders1/50
TenosynovitisMusculoskeletal and connective tissue disorders1/50

Baseline characteristics

Intent-to-Treat population

Age, Categorical
Age, Categorical(Participants)Three-part Treatment Regimen
<=18 years21
Between 18 and 65 years29
>=65 years0
Age, Continuous
Age, Continuous(years)Three-part Treatment Regimen
Mean21.8 ± 8
Sex: Female, Male
Sex: Female, Male(Participants)Three-part Treatment Regimen
Female33
Male17
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Three-part Treatment Regimen
Region of Enrollment
Region of Enrollment(Participants)Three-part Treatment Regimen
Germany50
Skin phototype
Skin phototype(Participants)Three-part Treatment Regimen
Phototype I1
Phototype II25
Phototype III21
Phototype IV3
Investigator Global Assessment
Investigator Global Assessment(Participants)Three-part Treatment Regimen
Mild37
Moderate13
Severe0
Acne duration
Acne duration(Years)Three-part Treatment Regimen
Mean9.8 ± 7.4

3 further baseline measures are reported on the registry.

08

Study locations

1 site
  • EGBERT Mi-Ran
    Münster, 48159, Germany
09

References and documents

Publications

  • Kim MR, Kerrouche N. Combination of benzoyl peroxide 5% gel with liquid cleanser and moisturizer SPF 30 in acne treatment results in high levels of subject satisfaction, good adherence and favorable tolerability. J Dermatolog Treat. 2018 Feb;29(1):49-54. doi: 10.1080/09546634.2017.1342758. Epub 2017 Jul 5. PubMed 28678647 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2019, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2015
First posted
Oct 28, 2015
Start
Aug 2015
Primary completionActual
Jan 2016
CompletionActual
Jan 2016
Results first posted
Feb 11, 2019
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02589405
Lead sponsor
Galderma R&D
Collaborators
Proinnovera GmbH
Responsible party
Sponsor
First posted
Oct 28, 2015
Start date
Aug 2015
Primary completion
Jan 2016
Completion
Jan 2016
Results posted
Feb 11, 2019
Last update
Feb 18, 2021

Study contacts

Mi-Ran EGBERT, MD
principal investigator · Proinnovera GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benzoyl Peroxide

Start the discussion